BCR-ABL tyrosine kinase inhibitors
A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.
BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).
Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.
BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Avg. Ratings |
|
|---|---|---|---|
| dasatinib systemic (Pro, More...) |
6 Review(s) | Rate It! | 9.5 |
| imatinib systemic (Pro, More...) |
14 Review(s) | Rate It! | 9.3 |
| nilotinib systemic (Pro, More...) |
9 Review(s) | Rate It! | 6.6 |
See also
Medical conditions associated with BCR-ABL tyrosine kinase inhibitors:
